File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Current perspective of stem cell therapies for cardiac regeneration

TitleCurrent perspective of stem cell therapies for cardiac regeneration
Authors
KeywordsAcute Myocardial Infarction
Bone Marrow-Derived Cells
Cardiac Progenitor Cells
Embryonic Stem Cells
Induced Pluripotent Stem Cells
Myocardial Ischemia
Skeletal Myoblasts
Issue Date2011
PublisherFuture Medicine Ltd. The Journal's web site is located at http://www.futuremedicine.com/loi/thy
Citation
Therapy, 2011, v. 8 n. 1, p. 69-82 How to Cite?
AbstractDespite recent advances in prevention and treatment of coronary artery disease, it remains the major cause of morbidity and mortality worldwide. There is an unmet need for treatment of ischemic cardiomyopathy caused by postmyocardial infarction, left ventricular remodeling or chronic myocardial ischemia. As a result, there is tremendous interest in developing stem cell therapies for prevention and treatment of ischemic cardiomyopathy. Although the mechanism remains unclear, the majority of preclinical studies demonstrate that different sources of cell-based therapy reduce the infarct size, and improve myocardial perfusion and contractile function. Recent results from randomized controlled clinical trials suggest that intracoronary or intramyocardial injection of bone marrow-derived cells may be a safe and feasible strategy for treatment of acute myocardial infarction as well as chronic myocardial ischemia. Furthermore, these studies have also provided initial evidence of clinical efficacy with modest, but significant improvement in left ventricular ejection fraction and functional status. However, most of these studies are limited by relatively small sample sizes and a short duration of follow-up, and the clinical efficacy of stem cell therapy in coronary artery disease needs to be confirmed by ongoing major clinical trials. In addition, further studies are also required to refine the optimal timing, cell types and mode of delivery, and to develop strategies to overcome the potential hurdles related to cell-based therapy. © 2011 Future Medicine Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/163352
ISSN
References

 

DC FieldValueLanguage
dc.contributor.authorLee, YKen_US
dc.contributor.authorSiu, CWen_US
dc.contributor.authorZhang, Yen_US
dc.contributor.authorTse, HFen_US
dc.date.accessioned2012-09-05T05:30:26Z-
dc.date.available2012-09-05T05:30:26Z-
dc.date.issued2011en_US
dc.identifier.citationTherapy, 2011, v. 8 n. 1, p. 69-82en_US
dc.identifier.issn1475-0708en_US
dc.identifier.urihttp://hdl.handle.net/10722/163352-
dc.description.abstractDespite recent advances in prevention and treatment of coronary artery disease, it remains the major cause of morbidity and mortality worldwide. There is an unmet need for treatment of ischemic cardiomyopathy caused by postmyocardial infarction, left ventricular remodeling or chronic myocardial ischemia. As a result, there is tremendous interest in developing stem cell therapies for prevention and treatment of ischemic cardiomyopathy. Although the mechanism remains unclear, the majority of preclinical studies demonstrate that different sources of cell-based therapy reduce the infarct size, and improve myocardial perfusion and contractile function. Recent results from randomized controlled clinical trials suggest that intracoronary or intramyocardial injection of bone marrow-derived cells may be a safe and feasible strategy for treatment of acute myocardial infarction as well as chronic myocardial ischemia. Furthermore, these studies have also provided initial evidence of clinical efficacy with modest, but significant improvement in left ventricular ejection fraction and functional status. However, most of these studies are limited by relatively small sample sizes and a short duration of follow-up, and the clinical efficacy of stem cell therapy in coronary artery disease needs to be confirmed by ongoing major clinical trials. In addition, further studies are also required to refine the optimal timing, cell types and mode of delivery, and to develop strategies to overcome the potential hurdles related to cell-based therapy. © 2011 Future Medicine Ltd.en_US
dc.languageengen_US
dc.publisherFuture Medicine Ltd. The Journal's web site is located at http://www.futuremedicine.com/loi/thyen_US
dc.relation.ispartofTherapyen_US
dc.subjectAcute Myocardial Infarctionen_US
dc.subjectBone Marrow-Derived Cellsen_US
dc.subjectCardiac Progenitor Cellsen_US
dc.subjectEmbryonic Stem Cellsen_US
dc.subjectInduced Pluripotent Stem Cellsen_US
dc.subjectMyocardial Ischemiaen_US
dc.subjectSkeletal Myoblastsen_US
dc.titleCurrent perspective of stem cell therapies for cardiac regenerationen_US
dc.typeArticleen_US
dc.identifier.emailSiu, CW:cwdsiu@hkucc.hku.hken_US
dc.identifier.emailTse, HF:hftse@hkucc.hku.hken_US
dc.identifier.authoritySiu, CW=rp00534en_US
dc.identifier.authorityTse, HF=rp00428en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.2217/thy.10.81en_US
dc.identifier.scopuseid_2-s2.0-78650933990en_US
dc.identifier.hkuros200850-
dc.identifier.hkuros208706-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-78650933990&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume8en_US
dc.identifier.issue1en_US
dc.identifier.spage69en_US
dc.identifier.epage82en_US
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridLee, YK=25958641200en_US
dc.identifier.scopusauthoridSiu, CW=7006550690en_US
dc.identifier.scopusauthoridZhang, Y=35785519300en_US
dc.identifier.scopusauthoridTse, HF=7006070805en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats